Annexon, Inc.
About Annexon, Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$206.7M
- Total assets
- $277.6M
- Market cap
- $866.7M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $216.4M
- Operating income
- -$216.4M
- Income tax
- $0
- Net income
- -$206.7M
- EPS (basic)
- $-1.34
- EPS (diluted)
- $-1.34
Balance sheet
- Total assets
- $277.6M
- Current assets
- $242.2M
- Total liabilities
- $65.9M
- Current liabilities
- $42.6M
- Shareholders’ equity
- $211.6M
Cash flow
- Operating cash flow
- -$186.4M
- Investing cash flow
- $190.1M
- Financing cash flow
- $108.9M
- Net cash flow
- $112.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $866.7M
- EPS (diluted)
- $-1.34
- Shares outstanding
- 169.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 24, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $206.7M.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Annexon, Inc..
Write a review
News about Annexon, Inc.
News & sentiment via Polygon.io
